Real-life studies in allergen immunotherapy

Purpose of review Real-life (or real-world) studies can provide information that cannot be derived from randomized controlled trials. This approach is currently becoming of relevance for many treatments. In recent years, the real-life method has been applied also to allergen immunotherapy, providing new insights on it. We reviewed herein the available literature on the argument. Recent findings Several prospective and retrospective studies on allergen immunotherapy in the real-world setting have been published, mostly in the last 5 years. Most of them focused on adverse events, compliance, and the long term/preventive effects, and evidenced an overall favorable profile for different products and different allergens. Summary Real life study provided novel information and evidenced those aspects of immunotherapy that worth a more detailed approach, without the strict limitations usually imposed by controlled randomized trials.

[1]  Kevin Crosby,et al.  Copyright 2021 , 2021, 2021 25th International Computer Science and Engineering Conference (ICSEC).

[2]  C. Escudero,et al.  Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study☆ , 2020, The World Allergy Organization journal.

[3]  P. Demoly,et al.  Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies? , 2020, Expert review of respiratory medicine.

[4]  G. Passalacqua,et al.  Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study , 2020, BioMed research international.

[5]  G. Passalacqua,et al.  Biologicals for severe asthma: what we can learn from real-life experiences? , 2020, Current opinion in allergy and clinical immunology.

[6]  Derya Ünal,et al.  Effects of Perennial Allergen Immunotherapy in Allergic Rhinitis in Patients with/without Asthma: A-Randomized Controlled Real-Life Study , 2020, International Archives of Allergy and Immunology.

[7]  Y. Nam,et al.  Efficacy of Allergen Immunotherapy for Allergic Asthma in Real World Practice , 2019, Allergy, asthma & immunology research.

[8]  P. Demoly,et al.  Contraindications to immunotherapy: a global approach , 2019, Clinical and Translational Allergy.

[9]  A. Sheikh,et al.  Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases , 2019, Clinical and Translational Allergy.

[10]  N. Papadopoulos,et al.  The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group , 2019, European Respiratory Journal.

[11]  A. Sheikh,et al.  Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. , 2019, The Journal of allergy and clinical immunology.

[12]  D. Golden,et al.  Real-life safety of 5-grass pollen tablet in 5-to-9-year-old children with allergic rhinoconjunctivitis. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  P. Demoly,et al.  Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France , 2019, Allergy.

[14]  G. Canonica,et al.  The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials , 2018, The World Allergy Organization journal.

[15]  Kamlesh Khunti,et al.  Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.

[16]  C. Bachert,et al.  Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma , 2018, Allergy.

[17]  J. Gagne,et al.  Using Real‐World Data to Extrapolate Evidence From Randomized Controlled Trials , 2018, Clinical pharmacology and therapeutics.

[18]  D. Larenas-Linnemann,et al.  What you should not miss from the systematic reviews and meta-analyses on allergen-specific immunotherapy in 2017 , 2018, Current opinion in allergy and clinical immunology.

[19]  S. Durham,et al.  Practice and safety of allergen‐specific immunotherapy for allergic rhinitis in the UK national health service: A report of “real world” clinical practice , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[20]  P. Devillier,et al.  Sublingual immunotherapy provides long‐term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real‐world database analysis , 2017, Allergy.

[21]  P. Demoly,et al.  European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real‐life clinical assessment , 2017, Allergy.

[22]  E. Valovirta,et al.  Real‐life safety of allergen immunotherapy in children and adolescents , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[23]  P. Demoly,et al.  The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[24]  C. Incorvaia,et al.  Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment. , 2016, European annals of allergy and clinical immunology.

[25]  Tomić Vesna,et al.  Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. , 2016, Iranian journal of allergy, asthma, and immunology.

[26]  J. Schmitt,et al.  Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study. , 2015, The Journal of allergy and clinical immunology.

[27]  C. Bachert,et al.  Allergen immunotherapy on the way to product-based evaluation—a WAO statement , 2015, The World Allergy Organization journal.

[28]  M. Caminati,et al.  Omalizumab management beyond clinical trials: the added value of a network model. , 2014, Pulmonary pharmacology & therapeutics.

[29]  P. Demoly,et al.  An EAACI “European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)”: the methodology , 2014, Clinical and Translational Allergy.

[30]  N. Scichilone,et al.  Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view. , 2014, Pulmonary Pharmacology & Therapeutics.

[31]  W. Shaikh,et al.  A prospective study on the safety of sublingual immunotherapy in pregnancy , 2012, Allergy.

[32]  P. Howarth,et al.  How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA‐GA2LEN statement , 2011, Allergy.

[33]  E. Magen,et al.  Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life. , 2008, The Israel Medical Association journal : IMAJ.

[34]  M Landi,et al.  The safety of sublingual immunotherapy with one or multiple pollen allergens in children , 2008, Allergy.

[35]  H. Schünemann,et al.  The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. , 2011, The Journal of allergy and clinical immunology.

[36]  O. Skjønsberg,et al.  How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? , 2005, Respiratory medicine.

[37]  L. Levi Stress and distress in response to psychosocial stimuli. Laboratory and real life studies on sympathoadrenomedullary and related reactions. , 1972, Acta medica Scandinavica. Supplementum.